ALAlicia Leiva

Alicia Leiva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alicia Leiva has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Continuation versus discontinuation of treatment for severe dementia: randomized, pragmatic, open-label, clinical trial to evaluate the efficacy of continuing drug treatment in patients with severe dementia (STOP-DEM)

    by Aina Soler, Guillem Amer, Alicia Leiva, Joana Ripoll, María Angeles Llorente, Alfonso Leiva, Joana Maria Taltavull, Rosa Molina, Joan Llobera

    Previous observational studies and clinical trials have shown that cholinesterase inhibitors (with or without memantine) provide benefit for patients with mild-to-moderate Alzheimer’s disease. However, the impact of treatment continuation after progression to severe disease is unknown. The main aim of this study is to evaluate the effect and safety of continuing treatment with ChEIs (with or without memantine) for patients with severe dementia. This randomized, pragmatic, open-label clinical trial with blinded evaluators will evaluate the efficacy of continuing drug treatment in patients with advanced dementia. A total of 302 community-dwelling patients with severe dementia, Alzheimer’s disease, with or without a coexisting diagnosis of vascular dementia, and a score of 10 or less on the Mini-Mental State Examination who received previous treatment with a cholinesterase inhibitor (with or without memantine) for at least 3 months, will be randomized to continue or discontinue drug treatment. Follow-up will be 12 months or until the primary endpoint is achieved. The primary endpoint is entry into institutional care and progression of disability, defined as a loss of 2 of 4 basic functions, or 6 of 11 instrumental functions, according to the Bristol Activities of Daily Living Scale at 12 months. The secondary outcomes are patient changes in functional and cognitive state, quality of life, and caregiver burden. We expect that the results of our study will allow to identify if there is clinical relevant impact for patients and caregivers between maintaining or halting pharmacological treatment. The study was prospectively registered in the REec (2017–000042-22) on May 11 2017 and ID ISRCTN12134230 on February 25 2019.


  • Open Access

    The behavioral impact of auditory and visual oddball distracters in a visual and auditory categorization tasks

    by Alicia Leiva, Fabrice Parmentier

    Past cross-modal oddball studies have shown that participants respond slower to visual targets following the presentation of an unexpected change in a stream of auditory distracters. In the present study we examined the extent to which this novelty distraction may transcend the sensory distinction between distracter and target. In separate blocks of trials, participants categorized digits presented auditorily or visually in the face of visual or auditory standard and oddball distracters. The results showed significant novelty distraction in the presence of auditory novel stimuli, irrespective of whether the targets were visual. Visual oddball distracters yielded no distraction, however, whether targets were visual or auditory. The results therefore suggest that novelty distraction was not mediated by the sensory modality of the target stimuli but by that of the distracter. Funding: Supported by the Spanish Ministry of Science and Innovation (PSI2009-08427).